Connelly to lead Lilly’s U.S. unit, joins elite group

Share this article:
Eli Lilly yesterday named Deirdre Connelly president of Lilly USA.
The role gives Connelly direct responsibility for an affiliate that generated $7 billion in 2004 sales and has 6,600 employees.
In the process, Connelly joins an elite and growing band of female pharma execs, including Christine Poon, worldwide chairman of medicines and nutritionals at Johnson & Johnson, Karen Katen, vice chairman of Pfizer, Margaret McGlynn, president of U.S. Human Health Care at Merck, and Carrie Cox, president, global pharmaceutical business at Schering-Plough.
Connelly was promoted from the position of senior vice president for human resources, which she held only since last August. Succeeding her in that role is Anthony Murphy, formerly executive director for human resources.
She reports to John Lechleiter, executive vice president of pharmaceutical operations, who has had the additional task of leading U.S. operations since last July.
After joining Lilly's field force in 1984, Connelly held various positions, including leader of its U.S. women's health business unit and executive director of human resources for Lilly USA.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...